Andrx Climbs on Hopes of Approval for Key Drug to buy online credit-report firm iPlace; Rambus is cleared in patent infringement case; plus other stocks in the news

AstraZeneca will not list two patents protecting the active ingredient of Prilosec in the FDA's Orange Book. By listing the patents, AstraZeneca could have delayed FDA approval of Andrx Group's (ADRX ) generic version of Prilosec. CIBC reiterated its strong buy rating on the company's stock.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.